Fibroblasts as a practical alternative to mesenchymal stem cells

Journal of Transitional Medicine

Our Chief Scientific Officer, Thomas Ichim, Ph.D. led a team in a thorough analysis of the advantage fibroblasts exhibit over mesenchymal stem cells.